Inovio Pharmaceuticals Inc. has announced results from a Phase 1 proof-of-concept clinical trial evaluating DNA-encoded monoclonal antibodies (DMAbs) for COVID-19. The results, now published in Nature Medicine, include data from all 39 participants up to week 72 of follow-up. The study demonstrated durable and tolerable expression of DMAbs, with effective target binding and confirmed functional activity through week 72. No immune rejection or anti-drug antibodies were detected in approximately 1,000 blood samples. The most common side effects reported were mild and temporary injection site reactions, such as pain and redness. No serious adverse events related to the study drug were observed. Further exploratory analyses of clinical samples are ongoing.